Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rg-547. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 known ✓ | P06493 | 19/20 | 1.00 |
| ▸ | CDK4 known ✓ | P11802 | 18/20 | 1.00 |
| ▸ | CDK2 known ✓ | P24941 | 18/20 | 1.00 |
| ▸ | CCND1 | P24385 | 18/20 | 1.00 |
| ▸ | CASK | O14936 | 1/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 1.00 |
| ▸ | CDKL5 | O76039 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | CDK14 | O94921 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | MAK | P20794 | 1/20 | 1.00 |
| ▸ | CDK11B | P21127 | 1/20 | 1.00 |
| ▸ | TTK | P33981 | 1/20 | 1.00 |
| ▸ | CLK1 | P49759 | 1/20 | 1.00 |
| ▸ | CLK2 | P49760 | 1/20 | 1.00 |
| ▸ | CLK3 | P49761 | 1/20 | 1.00 |
| ▸ | GSK3A | P49840 | 1/20 | 1.00 |
| ▸ | GSK3B | P49841 | 1/20 | 1.00 |
| ▸ | CDK7 | P50613 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rg-547 SCHEMBL2397067 | 1.00 | CDK1 (1.00) | CDK1CDK4CCND1CDK2CASK | |
| SCHEMBL3522526 | 0.95 | CDK1 (0.91) | CDK1CDK4CCND1CDK2CASK | |
| SCHEMBL3522463 | 0.94 | CDK1 (0.89) | CDK1CDK4CCND1CDK2CASK | |
| SCHEMBL4350447 | 0.93 | CDK1 (0.87) | CDK1CDK4CCND1CDK2CASK | |
| SCHEMBL4365008 | 0.93 | CDK1 (0.85) | CDK1CDK4CCND1CDK2CASK | |
| SCHEMBL4355436 | 0.92 | CDK1 (0.86) | CDK1CDK4CCND1CDK2CASK | |
| SCHEMBL4354399 | 0.92 | CDK1 (0.86) | CDK1CDK4CCND1CDK2CASK | |
| SCHEMBL14723511 | 0.92 | CDK1 (0.85) | CDK1CDK4CCND1CDK2CASK | |
| SCHEMBL3521770 | 0.92 | CDK1 (0.84) | CDK1CDK4CCND1CDK2CASK | |
| SCHEMBL4348141 | 0.91 | CDK1 (0.84) | CDK1CDK4CCND1CDK2CASK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293413-A1 | COMPOUND AND METHOD FOR TREATING CHEMOTHERAPY-RELATED GASTROINTESTINAL SIDE EFFECTS | ONQUALITY PHARMACEUTICALS CHINA LTD. (CN) | 2024-09-05 | — | — | US | claimed |
| EP-4353236-A1 | COMPOUND AND METHOD FOR TREATING CHEMOTHERAPY-RELATED GASTROINTESTINAL SIDE EFFECTS | OnQuality Pharmaceuticals China Ltd. (CN) | 2024-04-17 | — | — | EP | claimed |
| CN-117529322-A | Compounds and methods for treating chemotherapy-related gastrointestinal side effects | 上海岸阔医药科技有限公司 | 2024-02-06 | — | — | CN | claimed |
| WO-2022258001-A1 | COMPOUND AND METHOD FOR TREATING CHEMOTHERAPY-RELATED GASTROINTESTINAL SIDE EFFECTS | 上海岸阔医药科技有限公司 | 2022-12-15 | — | — | WO | claimed |
| US-20260053799-A1 | COMPOUNDS FOR TREATING CANCER | EVEXTA BIO (FR) | 2026-02-26 | — | — | US | disclosed |
| US-12539304-B2 | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor | PFIZER INC. (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| EP-4568662-A1 | COMPOUNDS FOR TREATING CANCER | Evexta Bio (FR) | 2025-06-18 | — | — | EP | disclosed |
| CN-119997942-A | Compounds for the treatment of cancer | 埃维克斯塔生物公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20240293413-A1 | COMPOUND AND METHOD FOR TREATING CHEMOTHERAPY-RELATED GASTROINTESTINAL SIDE EFFECTS | ONQUALITY PHARMACEUTICALS CHINA LTD. (CN) | 2024-09-05 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-4256086-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | Cedars-Sinai Medical Center (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230279491-A1 | TREATMENTS FOR A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | CEDARS-SINAI MEDICAL CENTER | 2023-09-07 | — | — | US | disclosed |
| US-20230117684-A1 | COMBINATION OF AN ANAPLASTIC LYMPHOMA KINASE INHIBITOR AND A CYCLIN DEPENDENT KINASE INHIBITOR | PFIZER INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4162076-A1 | TREATMENTS FOR A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | Cedars-Sinai Medical Center (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2022258001-A1 | COMPOUND AND METHOD FOR TREATING CHEMOTHERAPY-RELATED GASTROINTESTINAL SIDE EFFECTS | 上海岸阔医药科技有限公司 | 2022-12-15 | — | — | WO | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| WO-2022173333-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE. LTD. (SG) | 2022-08-18 | — | — | WO | disclosed |
| WO-2022119842-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | CEDARS-SINAI MEDICAL CENTER (US) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053799-A1 | COMPOUNDS FOR TREATING CANCER | NCOA1, AR, ESR2 | CDK1 949/4885CDK4 1973/4885CDK2 1129/4885 |
| US-20230117684-A1 | COMBINATION OF AN ANAPLASTIC LYMPHOMA KINASE INHIBITOR AND A CYCLIN DEPENDENT KINASE INHIBITOR | CDK4, CDK2, CDK6 | CDK1 10/4885CDK4 1/4885CDK2 2/4885 |
| US-12539304-B2 | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor | CDK4, CDK2, CDK6 | CDK1 9/4885CDK4 1/4885CDK2 2/4885 |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | UPF1, NLN, BRCA1 | CDK1 1087/4885CDK4 1095/4885CDK2 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.